Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Maurer, E; Nicoletti, R; Brandt, D; Klein, W.
Effect of calcium antagonists on cardiac performance in patients with dilatative cardiomyopathy evaluated by noninvasive methods.
CLIN CARDIOL. 1983; 6: 399-404.
Doi: 10.1002/clc.4960060809
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Co-Autor*innen der Med Uni Graz
- Nicoletti Rudolf
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- We present 14 patients with dilatative cardiomyopathy, proven by hemodynamic and angiographic assessment who received in a single-blind, randomized study, equipotent doses of the three calcium blockers: verapamil (0.1 mg/kg i.v., followed by an infusion of 0.01 mg/kg/min), nifedipin (20 mg sublingually), or diltiazem (0.2 mg/kg i.v., followed by infusion of 0.02 mg/kg/min). Before and after treatment in 8 patients systolic time intervals were recorded with an AVL-Myocard-Check (Q-S2, pre-ejection period, left ventricular ejection time, and pre-ejection period/left ventricular ejection time) and end-systolic and end-diastolic diameter, fractional shortening, and circumferential fiber shortening velocity were measured by M-mode echocardiography. In another 6 patients radionuclide ventriculography was performed before and after each treatment (ejection fraction, cardiac index). PEP/LVET increased slightly after verapamil (+ 15%) and decreased after nifedipin (-5%) and diltiazem (-3%), the changes being not significant. Fractional shortening and circumferential fiber shortening velocity however, decreased after verapamil (-5%, resp. -15%) and increased after nifedipin (+ 14%, resp. + 25%) and after diltiazem (+ 23%, resp. + 16%). In the radionuclide studies ejection fraction increased after verapamil (+ 9%), nifedipin (+ 14%), and diltiazem (+ 13%), while cardiac index remained unchanged with verapamil and nifedipin and increased with diltiazem (+ 14%). In conclusion there are no significant changes in myocardial performance with the calcium blockers verapamil, nifedipin, and diltiazem. However, under verapamil there is a tendency to deterioration of myocardial performance, while it was slightly improved after nifedipin and diltiazem. Calcium antagonists may be used safely, therefore, also in patients with impaired myocardial performance.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Calcium - antagonists and inhibitors
- Calcium Channel Blockers - pharmacology
- Cardiomyopathies - physiopathology
- Diltiazem - pharmacology
- Drug Therapy, Combination - pharmacology
- Echocardiography - pharmacology
- Electrocardiography - pharmacology
- Female - pharmacology
- Heart - radionuclide imaging
- Hemodynamic Processes - radionuclide imaging
- Humans - radionuclide imaging
- Male - radionuclide imaging
- Middle Aged - radionuclide imaging
- Nifedipine - pharmacology
- Random Allocation - pharmacology
- Vasodilator Agents - pharmacology
- Verapamil - pharmacology